Biology of the Epidermal Growth Factor Receptor Family (original) (raw)

References

1. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16:1647–55
   Article CAS PubMed Google Scholar
2. Hulit J., Lee R.J., Russell R.G., Pestell R.G. ErbB-2-induced mammary tumor growth: the role of cyclin D1 and p27Kip1. Biochem Pharmacol 2002; 64:827–836
   Article CAS PubMed Google Scholar
3. Balasenthil S., Sahin A.A., Barnes C.J., Wang R.-A., Pestell R.G., Vadlamudi R.K., Kumar R. P21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 2003; 10.1074/jbc.M309937200
   Google Scholar
4. Bange J., Zwick E., and Ullrich A. Molecular targets for breast cancer therapy and prevention. Nature Med 2001; 7:548–552
   CAS PubMed Google Scholar
5. deBono J.S., Rowinsky E.K. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 2002; 8:S19–S26
   PubMed Google Scholar
6. Shawver L.K., Slamon D., Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002; 1:117–123
   Article CAS PubMed Google Scholar
7. Yarden Y., Sliwkowski M.X. Untangling the ErbB signaling network. Nature Reviews Molecular Cell Biology 2001; 2:127–137
   Article CAS PubMed Google Scholar
8. Cho H.S. Leahy D.J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002; 297:1330–1333
   CAS PubMed Google Scholar
9. Garrett T.P.J., McKern N.M., Lou M.Z., Elleman T.C., Adams T.E., Lovrecz G.O., Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 2002; 110:763–773
   Article CAS PubMed Google Scholar
10. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110:775–787
    Article CAS PubMed Google Scholar
11. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor Cell 2002; 110:669–672
    Article CAS PubMed Google Scholar
12. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., Bourguignon L., Hung M.C. Nulcear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3:802–808
    CAS PubMed Google Scholar
13. Marti U., Wells A. The nuclear accumulation of a variant epidermal growth factor receptor (EGFR) lacking the transmembrane domain requires coexpression of a full-length EGFR. Mol Cell Biol Res Comm 2000; 3:8–14
    Article CAS Google Scholar
14. Ni C.Y., Murphy M.P., Golde T.E., Carpenter G. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001; 294:2179–81
    Article CAS PubMed Google Scholar
15. Komuro A., Nagai M., Navin N.E., Sudol M. WW domain-containing protein YAP associates with ErbB4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB4 that translocates to the nucleus. J Biol Chem 2003; 278:33334–41
    Article CAS PubMed Google Scholar
16. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nature Med 2002; 8:289–293
    CAS PubMed Google Scholar
17. Vadlamudi R. Mandal M. Adam L. Steinbach G. Mendelsohn J. Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999; 18:305–14
    CAS PubMed Google Scholar
18. Howe L.R., Subbaramaiah K., Patel J., Masferrer J.L., Deora A,. Hudis C., Thaler H.T., Muller W.J., Du B.H., Brown A.M.C., Dannenberg A.J. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer Cancer Res 2002; 62:5405–5407
    CAS PubMed Google Scholar
19. Andreasen P.A., Egelund R., Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57:25–40
    Article CAS PubMed Google Scholar
20. Liu D., Ghiso J.A.A., Estrada Y., Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma Cancer Cell 2002; 1:445–457
    Article CAS PubMed Google Scholar
21. Golubovskaya V., Beviglia L., Xu L.H., Earp H.S., Craven R., Cance W. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells J Biol Chem 2002; 277:38978–38987
    Article CAS PubMed Google Scholar
22. Xia L., Wang L.J., Chung A.S., Ivanov S.S., Ling M.Y., Dragoi A.M., Platt A., Gilmer T.M., Fu X.Y., Chin Y.E. Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J Biol Chem 2002; 277:30716–30723
    CAS PubMed Google Scholar
23. Ren Z.Y., Schaefer T.S. ErbB-2 activates Stat3 alpha in a Src-and JAK2-dependent manner. J Biol Chem 2002; 277:38486–38493
    CAS PubMed Google Scholar
24. Kijima T., Niwa H., Steinman R.A., Drenning S.D., Gooding W.E., Wentzel A.L., Xi S.C., Grandis J.R. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth & Differ 2002; 13:355–362
    CAS Google Scholar
25. Solbach C. Roller M. Ahr A. Loibl S. Nicoletti M. Stegmueller M. Kreysch HG. Knecht R. Kaufmann M. Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer. Int J Cancer. 2002; 101:390–394
    Article CAS PubMed Google Scholar
26. Agus D.B., Akita R.W., Fox W.D., Lewis G.D., Higgins B., Pisacane P.I., Lofgren J.A., Tindell C., Evans D.P., Maiese K., Scher H.I., Sliwkowski M.X. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002 2:127–137
    Article CAS PubMed Google Scholar
27. Ng S.S.W., Tsao M.S., Nicklee T., Hedley D.W. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 2002; 1:777–783
    CAS PubMed Google Scholar
28. Mellinghoff I.K., Tran C., Sawyers C.L. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res 2002; 62:5254–5259
    CAS PubMed Google Scholar
29. Xia W.L, Mullin R.J., Keith B.R, Liu L.H., Ma H., Rusnak D.W., Owens G., Alligood K.J., Spector N.L. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002 21:6255–6263
    CAS PubMed Google Scholar
30. Allen L.F., Lenehan P.F., Eiseman I.A., Elliot W.L., Fry D.W. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 2002; 29:11–21
    CAS PubMed Google Scholar
31. Sirotnak F.M. Studies with ZD1839 in preclinical models. Semin Oncol 2003; 30(Suppl 1):12–20
    CAS PubMed Google Scholar
32. Barnes C.J., Yarmand-Bagheri R., Manda, M., Yang Z., Clayman G.L., Kumar R. Suppression of Epidermal Growth Factor Receptor, MAPK and Pak1 Pathways and Invasiveness of Human Cutaneous Squamous Cancer Cells by the Tyrosine Kinase Inhibitor ZD1839 (‘Iressa’). Mol Cancer Ther 2003; 2:345–351
    CAS PubMed Google Scholar
33. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., Kaye S.B., Gianni L., Harris A., Bjork T., Averbuch S.D., Feyereislova A., Swaisland H., Rojo F., Albanell J. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292–4302
    Article CAS PubMed Google Scholar
34. Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J., Gibson K.H. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749–5754
    CAS PubMed Google Scholar
35. Herbst R.S., Maddox A.M., Small E.J., Rothenberg L., Small E.L., Rubin E.H., Baselga J., Rojo F., Hong W.K., Swaisland H., Averbuch S.D., Ochs J., LoRusso P.M. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. Journal of Clin Oncol 2002; 20:3815–3825
    CAS Google Scholar
36. Twombly R. Despite Concerns, FDA panel backs EGFR inhibitor. JNCI 2002; 94:1596–1597
    PubMed Google Scholar
37. Dowsett M., Haper-Wynne C., Boeddinghaus I., Salter J., M Hills M., Dixon M., Ebbs S., Gui G., Sacks N., Smith I. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor positive primary breast cancer. Cancer Res 2001; 61:8452–8458
    CAS PubMed Google Scholar
38. Kumar R., Wang R.-A., Mazumdar A., Talukder A.H., Mandal M., Yang Z., Bagheri-Yarmand R., Sahin A., Hortobagyi G., Adam L., Barnes C.J., Vadlamudi R.K. A naturally occurring MTA1 variant sequesters oestrogen receptor-⊔ in the cytoplasm. Nature 2002; 418:654–657
    Article CAS PubMed Google Scholar
39. Kumar R. Another tie that binds the MTA family to breast cancer. Cell 2003 113:142–143
    Article CAS PubMed Google Scholar
40. Lee S., Yang W.T., Lan K.H., Sellappan S., Klos K., Hortobagyi G., Hung M.C., Yu D.H. Enhanced sensitization to Taxol-induced apoptosis by Herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 2002 62:5703–5710
    CAS PubMed Google Scholar
41. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eirmann W., Wolter J., Pegram M. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783–792
    Article CAS PubMed Google Scholar
42. Bagheri-Yarmand R., Vadlamudi R.K., Wang R.A., Mendelsohn J., Kumar R. Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-betal-mediated angiogenesis. J Biol Chem 2000; 275:39451–39457
    Article CAS PubMed Google Scholar
43. Kumar R., Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol 2001; 28:27–32
    Article CAS PubMed Google Scholar
44. Pegram M.D., Reese D.M. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial factor. Semin Oncol 2002; 29:29–37
    CAS PubMed Google Scholar
45. CH Baker C.H., Solorzano C.C., Fidler I.J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002; 62:1996–2003
    Google Scholar
46. Santra M., Reed C.C., Iozzo R.V. Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope. J Biol Chem 2002; 277:35671–35681
    Article CAS PubMed Google Scholar
47. Cordero J.B., Cozzolino M., Lu Y., Vidal M. Slatopolsky E., Stahl P.D., Barbieri M.A., Dusso A. 1,25-dihydroxy vitamin D down-regulates cell membrane growth-and nuclear growth-promoting signals by the epidermal growth factor receptor. J Biol Chem 2002; 277(41):38965–38971
    Article CAS PubMed Google Scholar
48. Scott G.K., Marden C., Xu F., Kirk L., Benz C.C. Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen Mol Cancer Ther 2002; 1:385–392
    CAS PubMed Google Scholar
49. Hung M.C., Hortobagyi G.N., Ueno N.T. Development of clinical trial of E1 A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. Adv Exper Med Biol 2000; 465:171–80
    CAS Google Scholar
50. Asada S., Choi Y., Yamada M., Wang S.C., Hung M.C., Qin J., Uesugi M. External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. PNAS USA 2002; 99:12747–12752
    CAS PubMed Google Scholar
51. Feng J. Adsay NV. Kruger M. Ellis KL. Nagothu K. Majumdar APN. Sarkar FH. Expression of ERRP in normal and neoplastic pancreata and its relationship to clinicopathologic parameters in pancreatic adenocarcinoma. Pancreas 2002; 25:342–349
    Article CAS PubMed Google Scholar
52. Kim S., Zagozdzon R., Meisler A., Baleja J.D., Fu Y.G., Avraham S., Avraham H. Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK negative growth regulatory function in breast cancer. J Biol Chem 2002; 277:36465–36470
    CAS PubMed Google Scholar
53. Xu W.P., Marcu M., Yuan X.T., Mimnaugh E., Patterson C., Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2 Neu. PNAS USA 2002; 99:12847–12852
    CAS PubMed Google Scholar
54. Katz M., Shtiegman K., Tal-Or P., Yakir L., Mosesson Y., Harari D., Machluf Y., Asao H., Jovin T., Sugamura K., Yarden Y. Ligand-independent degradation of epidermal growth factor receptor involves receptor ubiquitylation and hgs, an adaptor whose ubiquitin-interacting motif targets ubiquitylation by Nedd4. Traffic 2002; 3:740–751
    Article CAS PubMed Google Scholar

Download references